Q2 Results Impact: NALCO, Torrent Pharma Surge; TRIL Hits Lower Circuit

The Indian stock market witnessed sharp movements on November 10, led by notable reactions to the Q2 results of key companies. While NALCO and Torrent Pharmaceuticals stole the limelight with strong gains, Transformers and Rectifiers (TRIL) faced heavy selling pressure, triggering the lower circuit.

The session highlighted how earnings announcements continue to influence stock performance, with investors responding quickly to strong results and cautioning around operational or governance challenges.

Market Performance: Mixed Sentiment Across Stocks

The broader market saw a split in sentiment as companies reported their quarterly earnings.

• NALCO climbed nearly 9% to ₹254.98, reaching an 11-month high.
• Torrent Pharma jumped around 7%, hitting a fresh 52-week high of ₹3,830.
• Transformers & Rectifiers (TRIL) fell 20% to ₹313.55, triggering the lower circuit.

The contrasting moves underline the market’s sharp sensitivity to operational performance and corporate governance updates.

Main News: Earnings Drive Stock Moves

Quarterly results formed the backbone of market sentiment today. Companies that reported strong revenue growth and profitability saw sharp gains, while firms facing challenges or negative news witnessed intense selling pressure.

Company Details: Deep Dive Into Q2 Numbers

NALCO Q2 FY26 Performance

National Aluminum Company (NALCO) reported a strong second quarter, reflecting growth in revenue and net profit:

• Net Profit (Consolidated): ₹1,430 crore, up 37% YoY from ₹1,046 crore in Q2 FY25
• Revenue from Operations: ₹4,292 crore, up 7% YoY
• Dividend: First interim dividend of ₹4 per equity share, with record date November 14 and payment by December 6

The results showcased NALCO’s steady performance in aluminu production and its ability to maintain growth momentum in a challenging environment.

Torrent Pharma Q2 FY26 Performance

Torrent Pharmaceuticals recorded robust growth, driven by strong international and domestic sales:

• Net Profit: ₹591 crore, up 30.5% YoY from ₹453 crore
• Revenue from Operations: ₹3,302 crore, up 14% YoY
• Sector Focus: Strong US and Brazil sales, consistent growth in India despite global supply disruptions

Torrent Pharma’s strong quarter pushed the stock to a new 52-week high, reflecting confidence in its operational execution and revenue expansion across multiple geographies.

Transformers & Rectifiers (TRIL) Q2 FY26 Performance

TRIL faced a challenging quarter, both in operational terms and due to external issues:

• Net Profit: ₹33.91 crore, down 25% YoY from ₹45.25 crore
• Revenue from Operations: ₹460 crore, showing a marginal decline
• EBITDA: ₹65 crore, with EBITDA margin at 13.81%
• Additional Update: The Company was debarred by the World Bank over alleged issues in a $486 million Nigeria power grid project.

Summary: Q2 Results Shape Stock Moves

The session on November 10 highlighted how earnings impact investor sentiment:

• NALCO surged to an 11-month high after strong revenue and profit growth
• Torrent Pharma hit a 52-week high, led by solid global and domestic sales.
• TRIL plunged 20%, reflecting operational and compliance challenges